Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 10, 2017, by Citius Pharmaceuticals, Inc., a Nevada corporation. The filing discloses the entry into material definitive agreements regarding debt financing and the restructuring of existing obligations.
Key Financial Metrics and Debt Obligations
The filing details two primary debt instruments involving Leonard Mazur, the Company's Executive Chairman, Secretary, and Director:
- Bridge Note: A new convertible future advance promissory note with a principal capacity of up to $1,500,000. As of the filing date, $120,000 is outstanding (an advance made in April).
- A&R Note: A consolidated convertible promissory note created by converting preexisting demand promissory notes with an aggregate principal amount of $2,500,000.
- Total Outstanding Debt Disclosed: $2,620,000 ($120,000 Bridge Note + $2,500,000 A&R Note).
- Interest Rate: The Bridge Note bears interest at the "Prime Rate" plus 1%. The A&R Note terms regarding interest remain unchanged from prior filings.
- Maturity Date: Both notes mature on the earlier of December 31, 2017, or conversion.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or overall liquidity beyond the specific debt obligations listed above.
Material Changes and Terms
The primary material change is the formalization of the Bridge Note and the consolidation of $2,500,000 in preexisting notes into the A&R Note. Key terms include:
- Conversion Rights: Both notes are convertible into common stock at a price equal to 75% of the price per share paid by investors in a future Securities Offering (S-1).
- Most Favored Nation Clause: If the Company enters into third-party debt financing with better terms while the Bridge Note is outstanding, the Lender may elect to amend the Bridge Note to incorporate those terms.
Outlook, Risks, and Contingencies
The Company's ability to repay or convert this debt is contingent upon the successful completion of a Securities Offering pursuant to an S-1 registration statement. The filing notes that the full terms of the Financing Documents will be included in the upcoming Form 10-Q for the quarter ended March 31, 2017. The involvement of an insider (Executive Chairman) as the sole lender for these significant amounts represents a related-party transaction risk.
Investor Verification Checklist
- Verify the status of the S-1 registration statement required for the conversion of these notes.
- Review the upcoming Form 10-Q for the full text of the Financing Documents and any additional interest terms on the A&R Note.
- Confirm the Company's current cash position to assess the ability to service the $2,620,000 in debt if the Securities Offering is delayed or fails.
- Check for any subsequent filings regarding the "better terms" clause if the Company pursues third-party financing before December 31, 2017.